Open Payments

National Jewish Health

Type
Teaching hospital
Where
Denver, CO
Medicare CCN
060107
Received
$5,056,591 in 339 records, 2020 ($1,937,594 general, $3,118,996 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment100$1,937,594
2020Research payment239$3,118,996

By company

CompanyRecordsAmountYears
Regeneron Pharmaceuticals, Inc.75$1,070,0392020
Boehringer Ingelheim Pharmaceuticals, Inc.13$975,3322020
Novartis Pharmaceuticals Corporation3$555,8542020
Genentech, Inc.12$520,0582020
PFIZER INC.8$288,9792020
VERTEX PHARMACEUTICALS INCORPORATED7$244,2632020
LEO Pharma AS5$224,6872020
AstraZeneca Pharmaceuticals LP11$156,5342020
Incyte Corporation28$119,4722020
E.R. Squibb & Sons, L.L.C.1$95,5532020
BioMarin Pharmaceutical Inc.7$72,7642020
Eli Lilly and Company2$72,1542020
Gilead Sciences, Inc.2$67,2932020
Kadmon Corporation LLC1$56,4072020
GENZYME CORPORATION3$56,1332020
Merck Sharp & Dohme LLC7$49,9902020
Teva Pharmaceuticals USA, Inc.1$47,2802020
Boehringer Ingelheim Pharma GmbH & Co.KG15$35,5932020
Takeda Pharmaceuticals U.S.A., Inc.5$34,5672020
United Therapeutics Corporation10$33,0042020
Janssen Research & Development, LLC4$31,7282020
Aimmune Therapeutics, Inc.8$30,8912020
Alexion Pharmaceuticals, Inc.48$29,5182020
Actelion Pharmaceuticals, Ltd1$26,4542020
AstraZeneca UK Limited1$26,0002020
Horizon Therapeutics plc1$25,0002020
Mallinckrodt Hospital Products Inc.3$24,1902020
Becton, Dickinson and Company9$10,9062020
AstraZeneca AB1$10,0002020
Beckman Coulter, Inc.1$10,0002020
Siemens Medical Solutions USA, Inc.2$8,4842020
Ipsen Bioscience Inc.2$8,1982020
GlaxoSmithKline, LLC.3$7,5002020
Bio-Rad Laboratories, Inc.4$6,2422020
CSL Behring3$4,2502020
Allergan, Inc.2$3,6542020
Genentech USA, Inc.1$3,0002020
Mylan Pharmaceuticals Inc.1$2,5002020
Optinose US, Inc.1$2,5002020
Amgen Inc.2$2,5002020
Advanced Respiratory, Inc1$2,0002020
SANOFI US SERVICES INC.2$1,7922020
ABBVIE INC.2$1,7472020
Boehringer Ingelheim International GmbH13$7742020
VIVUS LLC2$5872020
Boehringer Ingelheim Limited3$1492020
EMD Millipore Corporation2$582020

By nature of payment

NatureRecordsAmount
Research payment239$3,118,996
Grant12$1,749,113
Compensation for services other than consulting, including serving as faculty or as a speaker at a v56$111,714
Royalty or License18$41,079
Space rental or facility fees (teaching hospital only)11$28,500
Education2$7,000
Charitable Contribution1$187

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31AstraZeneca Pharmaceuticals LP$11,361Research paymentIn-kind items and servicesA Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inf2020
2020-12-31Siemens Medical Solutions USA, Inc.$8,297Research paymentCash or cash equivalentNJHHumphriesCOPDCombinationCT2020
2020-12-31AstraZeneca Pharmaceuticals LP$480Research paymentIn-kind items and servicesA Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet2020
2020-12-31AstraZeneca Pharmaceuticals LP$265Research paymentIn-kind items and servicesStudy to evaluate the efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adults with oral cortico2020
2020-12-31Siemens Medical Solutions USA, Inc.$187Charitable ContributionIn-kind items and services2020
2020-12-31Aimmune Therapeutics, Inc.$18Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2020
2020-12-29United Therapeutics Corporation$3,538Research paymentCash or cash equivalentTYVASO Drug, PAHAN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI2020
2020-12-24Janssen Research & Development, LLC$2,612Research paymentCash or cash equivalentA Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-se2020
2020-12-22United Therapeutics Corporation$10,388Research paymentCash or cash equivalentORENITRAM Drug, PAHA Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-12-21Aimmune Therapeutics, Inc.$3,998Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2020
2020-12-20Boehringer Ingelheim Pharmaceuticals, Inc.$124,991Research paymentCash or cash equivalentA randomized parallel group study evaluating the e2020
2020-12-18Regeneron Pharmaceuticals, Inc.$716,825Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYEFFECT OF DUPILUMAB (ANTI-IL4RA) ON THE HOST-MICROBE INTERFACE IN ATOPIC DERMATITIS2020
2020-12-18Regeneron Pharmaceuticals, Inc.$5,937Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYEFFECT OF DUPILUMAB (ANTI-IL4RA) ON THE HOST-MICROBE INTERFACE IN ATOPIC DERMATITIS2020
2020-12-18Genentech, Inc.$1,114Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2020
2020-12-17Regeneron Pharmaceuticals, Inc.$940Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-12-14Janssen Research & Development, LLC$17,616Research paymentCash or cash equivalentA Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-se2020
2020-12-14Becton, Dickinson and Company$5,000EducationIn-kind items and services2020
2020-12-14Becton, Dickinson and Company$5,000Royalty or LicenseCash or cash equivalentBD Pharmingen Device, Cell Analysis2020
2020-12-10Regeneron Pharmaceuticals, Inc.$1,769Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-12-07Genentech, Inc.$65,581Research paymentCash or cash equivalentEsbriet Biological, ImmunologySTUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS2020
2020-12-07Genentech, Inc.$54,008Research paymentCash or cash equivalentEsbriet Biological, ImmunologySTUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS2020
2020-12-07Genentech, Inc.$30,048Research paymentCash or cash equivalentEsbriet Biological, ImmunologySTUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS2020
2020-12-07Genentech, Inc.$15,024Research paymentCash or cash equivalentEsbriet Biological, ImmunologySTUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS2020
2020-12-07Amgen Inc.$1,250Royalty or LicenseCash or cash equivalent2020
2020-12-07Amgen Inc.$1,250Royalty or LicenseCash or cash equivalent2020
2020-12-04BioMarin Pharmaceutical Inc.$3,220Research paymentCash or cash equivalentPalynziq Drug, PKUAn Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos2020
2020-12-02Merck Sharp & Dohme LLC$4,833Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2020
2020-12-01AstraZeneca Pharmaceuticals LP$29,400GrantCash or cash equivalent2020
2020-12-01Incyte Corporation$2,716Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-12-01Boehringer Ingelheim Pharma GmbH & Co.KG$63Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-12-01Boehringer Ingelheim International GmbH$63Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-11-30Janssen Research & Development, LLC$6,500Research paymentCash or cash equivalentUptravi (Selexipag): the users drug registry2020
2020-11-27Merck Sharp & Dohme LLC$1,878Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2020
2020-11-26Teva Pharmaceuticals USA, Inc.$47,280Research paymentCash or cash equivalentCINQAIR Biological, RespiratoryReslizumab in the Treatment of EGPA2020
2020-11-25LEO Pharma AS$90,312Research paymentCash or cash equivalentTRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS2020
2020-11-25LEO Pharma AS$57,500Research paymentCash or cash equivalentTRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS2020
2020-11-24United Therapeutics Corporation$5,768Research paymentCash or cash equivalentORENITRAM Drug, PAHA Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-11-19Regeneron Pharmaceuticals, Inc.$616Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-11-19Regeneron Pharmaceuticals, Inc.$224Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-11-19Becton, Dickinson and Company$197Royalty or LicenseCash or cash equivalentBD Pharmingen Device, Cell Analysis2020
2020-11-19Becton, Dickinson and Company$39Royalty or LicenseCash or cash equivalentBD Pharmingen Device, Cell Analysis2020
2020-11-18Gilead Sciences, Inc.$55,293Research paymentCash or cash equivalentCayston Drug, RESPUltrasensitive detection of reductions in CF airway inflammation2020
2020-11-18LEO Pharma AS$25,937Research paymentCash or cash equivalentTRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS2020
2020-11-18Incyte Corporation$8,000Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-11-18Incyte Corporation$500Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-11-18Bio-Rad Laboratories, Inc.$46Royalty or LicenseCash or cash equivalentAntibody Device, Market Research2020
2020-11-10Aimmune Therapeutics, Inc.$2,048Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYREAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSI2020
2020-11-06Regeneron Pharmaceuticals, Inc.$11,587Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-11-06Incyte Corporation$1,363Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-11-06Incyte Corporation$1,363Research paymentCash or cash equivalentPD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell car2020
2020-11-05Regeneron Pharmaceuticals, Inc.$224Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-11-04Incyte Corporation$9,227Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-11-03Genentech, Inc.$124,206Research paymentCash or cash equivalentXolair Biological, ImmunologyTHE IMPACT OF INCREASED IGE2020
2020-11-01Boehringer Ingelheim Pharma GmbH & Co.KG$62Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-11-01Boehringer Ingelheim International GmbH$62Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-10-27Novartis Pharmaceuticals Corporation$70,504Research paymentCash or cash equivalentMAS825F DrugA PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR BLINDED, MULTI-CENTER STUDY TO ASSESS EFFICACY A2020
2020-10-27Beckman Coulter, Inc.$10,000Royalty or LicenseCash or cash equivalent2020
2020-10-27Boehringer Ingelheim Limited$34Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-10-26BioMarin Pharmaceutical Inc.$7,935Research paymentCash or cash equivalentPalynziq Drug, PKUAn Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos2020
2020-10-22Regeneron Pharmaceuticals, Inc.$560Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-20United Therapeutics Corporation$5,049Research paymentCash or cash equivalentORENITRAM Drug, PAHA Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients2020
2020-10-16Genentech, Inc.$1,781Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2020
2020-10-15Regeneron Pharmaceuticals, Inc.$9,786Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-10-15Alexion Pharmaceuticals, Inc.$7,780Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-10-15Regeneron Pharmaceuticals, Inc.$359Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$359Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$359Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$293Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$259Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$259Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$259Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-15Regeneron Pharmaceuticals, Inc.$259Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-14United Therapeutics Corporation$3,626Research paymentCash or cash equivalentTYVASO Drug, PAHA MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST2020
2020-10-08Regeneron Pharmaceuticals, Inc.$5,058Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-10-08Regeneron Pharmaceuticals, Inc.$1,275Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-10-06Eli Lilly and Company$62,154Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF LY3127804 IN PATIENTS WHO ARE HOSPITALIZED WITH PNEUMO2020
2020-10-01Boehringer Ingelheim Pharma GmbH & Co.KG$62Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-10-01Boehringer Ingelheim International GmbH$62Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-09-29Boehringer Ingelheim Pharmaceuticals, Inc.$72Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-09-28GENZYME CORPORATION$11,133Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyOpen Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S2020
2020-09-24Regeneron Pharmaceuticals, Inc.$25,800Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-09-24Regeneron Pharmaceuticals, Inc.$438Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-09-24Merck Sharp & Dohme LLC$44Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2020
2020-09-23Regeneron Pharmaceuticals, Inc.$940Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-09-17Regeneron Pharmaceuticals, Inc.$2,172Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-09-17Regeneron Pharmaceuticals, Inc.$1,377Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-09-16E.R. Squibb & Sons, L.L.C.$95,553Research paymentCash or cash equivalentIdentification of Disease Progression Biomarkers in the National Jewish Health IPF cohort2020
2020-09-16Incyte Corporation$822Research paymentCash or cash equivalentPD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell car2020
2020-09-16Incyte Corporation$822Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-09-15AstraZeneca Pharmaceuticals LP$1,400Research paymentCash or cash equivalentA Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet2020
2020-09-14Boehringer Ingelheim Pharmaceuticals, Inc.$58,495Research paymentCash or cash equivalentInterstitial Lung Disease in Early Rheumatoid Arth2020
2020-09-11Genentech, Inc.$5,000Royalty or LicenseCash or cash equivalentNon-Covered Product Drug, None2020
2020-09-09United Therapeutics Corporation$700Research paymentCash or cash equivalentTYVASO Drug, PAHAN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI2020
2020-09-08Aimmune Therapeutics, Inc.$6,117Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2020
2020-09-08Aimmune Therapeutics, Inc.$2,739Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2020
2020-09-08Incyte Corporation$117Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-09-04SANOFI US SERVICES INC.$1,542Research paymentCash or cash equivalentDUPIXENT Biological, ImmunologyOpen-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A2020
2020-09-03BioMarin Pharmaceutical Inc.$14,775Research paymentCash or cash equivalentPalynziq Drug, PKUAn Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos2020
2020-09-01Eli Lilly and Company$10,000Research paymentCash or cash equivalent2020
2020-09-01Boehringer Ingelheim International GmbH$60Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-09-01Boehringer Ingelheim Pharma GmbH & Co.KG$60Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-08-26Merck Sharp & Dohme LLC$452Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot2020
2020-08-26Boehringer Ingelheim Pharma GmbH & Co.KG$90Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-08-25Becton, Dickinson and Company$120Royalty or LicenseCash or cash equivalentBD Pharmingen Device, Cell Analysis2020
2020-08-20Regeneron Pharmaceuticals, Inc.$3,971Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-08-18EMD Millipore Corporation$30Royalty or LicenseCash or cash equivalent Device, DIAGNOSTIC TESTING2020
2020-08-14Regeneron Pharmaceuticals, Inc.$8,976Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-08-14Regeneron Pharmaceuticals, Inc.$6,627Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-08-14Regeneron Pharmaceuticals, Inc.$6,396Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-08-14Regeneron Pharmaceuticals, Inc.$4,647Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-08-14Regeneron Pharmaceuticals, Inc.$2,578Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-08-14Bio-Rad Laboratories, Inc.$1,899Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLiquichek Device, Controls2020
2020-08-12CSL Behring$750Research paymentCash or cash equivalentStudy NJH-A1520 - Referral Lab Testing2020
2020-08-09Boehringer Ingelheim Pharmaceuticals, Inc.$5Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF ILD extension2020
2020-08-06ABBVIE INC.$970Research paymentCash or cash equivalentCREON Drug, ENDOCRINOLOGYP12-7922020
2020-08-06VIVUS LLC$326Research paymentCash or cash equivalentPANCREAZE Drug, CYSTIC FIBROSISLong-term Study in US Cystic Fibrosis2020
2020-08-03Incyte Corporation$28,453Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-08-01VERTEX PHARMACEUTICALS INCORPORATED$14,641Research paymentCash or cash equivalentEvaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype2020
2020-08-01Alexion Pharmaceuticals, Inc.$7,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-08-01Boehringer Ingelheim International GmbH$60Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-08-01Boehringer Ingelheim Pharma GmbH & Co.KG$60Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-07-30Regeneron Pharmaceuticals, Inc.$7,770Research paymentCash or cash equivalentSample acquisition study from Eculizumab treated CHAPLE patients and health patients for understanding disease biomarker2020
2020-07-29Incyte Corporation$6,609Research paymentCash or cash equivalentTRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis2020
2020-07-28Regeneron Pharmaceuticals, Inc.$4,444Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-07-24Regeneron Pharmaceuticals, Inc.$6,305Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-07-23Regeneron Pharmaceuticals, Inc.$7,337Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-07-22AstraZeneca Pharmaceuticals LP$50,176Research paymentCash or cash equivalentFASENRA Drug, RespiratoryBenralizumab in the Treatment of EGPA Study2020
2020-07-16Regeneron Pharmaceuticals, Inc.$2,183Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-07-13Actelion Pharmaceuticals, Ltd$26,454Research paymentCash or cash equivalentOPsumit Users Registry2020
2020-07-10Regeneron Pharmaceuticals, Inc.$10,333Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-07-09Boehringer Ingelheim Pharma GmbH & Co.KG$34,606Research paymentCash or cash equivalentResearch Collaboration2020
2020-07-09Regeneron Pharmaceuticals, Inc.$5,195Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-07-02Regeneron Pharmaceuticals, Inc.$9,748Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-07-02Regeneron Pharmaceuticals, Inc.$9,437Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-07-01Genentech, Inc.$10,094Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyNEOADJUVANT NSCLC2020
2020-07-01Aimmune Therapeutics, Inc.$5,823Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2020
2020-07-01Boehringer Ingelheim Pharma GmbH & Co.KG$60Research paymentIn-kind items and servicesEmphysema Progression Biomarker Study2020
2020-07-01Boehringer Ingelheim International GmbH$60Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYNintedanib in PF-ILD (extension)2020
2020-06-26Regeneron Pharmaceuticals, Inc.$8,231Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-18Regeneron Pharmaceuticals, Inc.$6,806Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-18Regeneron Pharmaceuticals, Inc.$1,557Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-06-11LEO Pharma AS$34,062Research paymentCash or cash equivalentTRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS2020
2020-06-11Regeneron Pharmaceuticals, Inc.$9,127Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$7,628Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$7,628Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$7,409Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$7,026Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$6,806Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$6,514Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-11Regeneron Pharmaceuticals, Inc.$3,513Research paymentCash or cash equivalentKEVZARA Biological, INFLAMMATION AND IMMUNOLOGYAn Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for2020
2020-06-04Regeneron Pharmaceuticals, Inc.$2,929Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2020
2020-06-04Regeneron Pharmaceuticals, Inc.$690Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-06-04Regeneron Pharmaceuticals, Inc.$562Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-06-04Regeneron Pharmaceuticals, Inc.$300Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-06-04Regeneron Pharmaceuticals, Inc.$248Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO2020
2020-06-03Takeda Pharmaceuticals U.S.A., Inc.$12,593Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTAKHZYRO Biological, IMMUNOLOGY2020
2020-06-03Takeda Pharmaceuticals U.S.A., Inc.$7,214Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTAKHZYRO Biological, IMMUNOLOGY2020
2020-06-03Takeda Pharmaceuticals U.S.A., Inc.$6,628Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTAKHZYRO Biological, IMMUNOLOGY2020
2020-06-03Takeda Pharmaceuticals U.S.A., Inc.$5,372Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTAKHZYRO Biological, IMMUNOLOGY2020
2020-06-03Takeda Pharmaceuticals U.S.A., Inc.$2,758Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTAKHZYRO Biological, IMMUNOLOGY2020
2020-06-01Ipsen Bioscience Inc.$4,099Research paymentCash or cash equivalentONIVYDE Drug, OncologyRESILIENT A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection ONIVYDE Versus Topotecan in Patients W2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020
2020-06-01Alexion Pharmaceuticals, Inc.$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2020

The latest 200 records of 339.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Denver CountyDenver city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.

MeasurePlace (city or town)
Denver, CO
County
Denver County, CO
State
Colorado
Population B01003718,877718,8775,862,189
Population, 2020 census P1715,522715,5225,773,714
Median age B0100235.335.337.7
Under 18 B0100118.0%18.0%21.0%
65 and over B0100112.5%12.5%15.6%
Households B11001335,428335,4282,374,218
Foreign born B0500214.5%14.5%9.8%
Median household income B19013$94,718$94,718$95,470
Median family income B19113$124,743$124,743$119,139
Per capita income B19301$64,163$64,163$52,636
Poverty rate B1700111.2%11.2%9.4%
Unemployment rate B230254.9%4.9%4.6%
Civilian labor force B23025447,681447,6813,235,476
Mean commute (minutes) B0801324.924.925.2
Bachelor's degree or higher B1500356.5%56.5%45.7%
Housing units B25001359,581359,5812,589,053
Owner-occupied B2500348.8%48.8%66.2%
Renters B2500351.2%51.2%33.8%
Median home value B25077$616,000$616,000$539,400
Median gross rent B25064$1,831$1,831$1,761
White, not Hispanic B0300254.0%54.0%64.8%
Black B030028.6%8.6%3.8%
Hispanic or Latino B0300228.0%28.0%22.5%
Asian B030023.6%3.6%3.2%
American Indian and Alaska Native B030020.3%0.3%0.4%

Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); Unemployment rate: 3.0% in Sep 2016 to 4.1% in Sep 2026; low 2.4%, high 11.7% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.